Evidence mapPaperPMID 35996147Full record

Trial reportCardiovascular diabetology2022

A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.

Hertzel C Gerstein, Chinthanie Ramasundarahettige, Alvero Avezum, Jan Basile, Ignacio Conget, William C Cushman, Gilles R Dagenais, Edward Franek, Mark Lakshmanan, Fernando Lanas and 10 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Cardiovascular diabetology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01394952. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01394952 phase3completed

The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)

Ran2011Enrolled9,901Registered outcomes6Posted comparisons8ConditionsCardiovascular Disease, Diabetes Mellitus, Type 2ArmsDulaglutide, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 11 countries.

Hertzel C GersteinPopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada. gerstein@mcmaster.ca.
Chinthanie RamasundarahettigePopulation Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
Alvero AvezumInternational Research Center, Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil.
Jan BasileMedical University of South Carolina, Charleston, SC, USA.
Ignacio CongetEndocrinology and Nutrition Department, University of Barcelona, Barcelona, Spain.
William C CushmanDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Gilles R DagenaisInstitut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec, Canada.
Edward FranekMossakowski Clinical Research Center, Polish Academy of Sciences, Warsaw, Poland.
Mark LakshmananEli Lilly and Company, Indianapolis, IN, USA.
Fernando LanasUniversidad de La Frontera, Temuca, Chile.
Lawrence A LeiterSt. Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Canada.
Nana PogosovaNational Medical Research Center of Cardiology, Moscow, Russia.
Jeffrey ProbstfieldUniversity of Washington, Seattle, USA.
Peter J RaubenheimerDepartment of Medicine, University of Cape Town, Cape Town, South Africa.
Matthew RiddleDepartment of Medicine, Oregon Health & Science University Portland, Oregon, USA.
Jonathan ShawBaker Heart and Diabetes Institute, Melbourne, Australia.
Wayne H-H SheuDivision of Endocrinology and Metabolism, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Theodora Temelkova-KurktschievRobert Koch Medical Center, Sofia, Bulgaria.
Ibrahim TurfandaEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Denis XavierSt. John's Research Institute, St. John's National Academy of Health Sciences, Bangalore, India.
Eli Lilly (United States) · USPopulation Health Research Institute · CABaker Heart and Diabetes Institute · AUHospital Alemão Oswaldo Cruz · BRInstitut Universitaire de Cardiologie et de Pneumologie de Québec · CAMedical University of South Carolina · USNational Medical Research Center of Cardiology · RUOregon Health & Science University · USPolish Academy of Sciences · PLSt. John's National Academy of Health Sciences · INTaipei Veterans General Hospital · TWUniversidad de La Frontera · CLUniversitat de Barcelona · ESUniversity of Cape Town · ZAUniversity of Tennessee Health Science Center · USUniversity of Toronto · CAUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe estimated glomerular filtration rate (eGFR) and the albumin-to-creatinine ratio (ACR) are risk factors for diabetes-related outcomes. A composite that captures information from both may provide a simpler way of assessing risk.

methods9115 of 9901 Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) participants with both an ACR and eGFR at baseline were included in this post hoc epidemiologic analysis. The hazard of higher baseline levels of 1/eGFR and natural log transformed ACR (calculated as ln [ACR × 100] to eliminate negative values) and their interaction for incident major adverse cardiovascular events (MACE), kidney outcomes, and deaths was estimated. The hazard of the geometric mean of these two baseline measures (the kidney disease index or KDI) was also assessed.

resultsA non-linear relationship was observed between 1/eGFR and all three outcomes, and between ln [ACR × 100] and the kidney outcome. There was also a negative interaction between these two risk factors with respect to MACE and death. Conversely, a linear relationship was noted between the KDI and all three outcomes. People in the highest KDI fifth experienced the highest incidence of MACE, death, and the kidney outcome (4.43, 4.56, and 5.55/100 person-years respectively). C statistics for the KDI were similar to those for eGFR and albuminuria.

conclusionsThe KDI combines the baseline eGFR and ACR into a novel composite risk factor that has a simple linear relationship with incident serious outcomes in people with diabetes and additional CV risk factors. Trial Registration clinicaltrials.gov NCT01394952.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Kidney DiseasesAlbuminsAlbuminuriaCreatinineGlomerular Filtration RateHumansKidneyRisk FactorsAlbuminsCreatinineAlbuminuriaCardiovascular OutcomesKidneyKidney OutcomesRisk Factor

Identifiers

PMID35996147
PMCPMC9396793
OpenAlexW4292641312

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.